Literature DB >> 2046613

Clinical implementation of stereotaxic brain implant optimization.

U F Rosenow1, J B Wojcicka.   

Abstract

This optimization method for stereotaxic brain implants is based on seed/strand configurations of the basic type developed for the National Cancer Institute (NCI) atlas of regular brain implants. Irregular target volume shapes are determined from delineation in a stack of contrast enhanced computed tomography scans. The neurosurgeon may then select up to ten directions, or entry points, of surgical approach of which the program finds the optimal one under the criterion of smallest target volume diameter. Target volume cross sections are then reconstructed in 5-mm-spaced planes perpendicular to the implantation direction defined by the entry point and the target volume center. This information is used to define a closed line in an implant cross section along which peripheral seed strands are positioned and which has now an irregular shape. Optimization points are defined opposite peripheral seeds on the target volume surface to which the treatment dose rate is prescribed. Three different optimization algorithms are available: linear least-squares programming, quadratic programming with constraints, and a simplex method. The optimization routine is implemented into a commercial treatment planning system. It generates coordinate and source strength information of the optimized seed configurations for further dose rate distribution calculation with the treatment planning system, and also the coordinate settings for the stereotaxic Brown-Roberts-Wells (BRW) implantation device.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2046613     DOI: 10.1118/1.596712

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  2 in total

1.  Mixed integer programming optimization models for brachytherapy treatment planning.

Authors:  R J Gallagher; E K Lee
Journal:  Proc AMIA Annu Fall Symp       Date:  1997

Review 2.  Brachytherapy for brain tumors.

Authors:  Todd W Vitaz; Peter C Warnke; Viviane Tabar; Philip H Gutin
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.